Dec 18, 2023 | Robin Tuohy, SGL Blogs
There is so much happening at ASH with the #IMFASH23 Team reporting in their blogs and tweets, that I’m trying to read those and then provide you with something you’ve not already read. On Saturday at #ASH23, there was a Health Services and Quality Improvement session...
Dec 18, 2023 | Robin Tuohy, SGL Blogs
I’ve waited to post my “Pre-ASH blog” so that I was able to take some photos to give you a perspective of what ASH is like before the meeting. First, we are grateful to the International Myeloma Foundation (IMF) for initiating this program, the first to bring myeloma...
Dec 18, 2023 | Jessie Daw, SGL Blogs
Attending the 65th American Society of Hematology (ASH) meeting as a patient advocate was an enlightening experience that ventured far beyond medical jargon and research presentations. Attending a whirlwind of sessions, even virtually, my days were filled with...
Dec 18, 2023 | Barbara Davis, SGL Blogs
Monday, Dec. 11 was another busy day. Lots of presentations which I’ll summarize below: Teclistamab retrospective of its use in relapsed/refractory multiple myeloma (RRMM) showed infections, particularly respiratory infections, also liver problems. I’m guessing I’ll...
Dec 15, 2023 | Jessie Daw, SGL Blogs
Attending the 65th Annual Meeting and Exposition of the American Society of Hematology meeting virtually, most presentations discuss the biological intricacies and physical treatments for myeloma. However, some research focuses on the quality of life for patients. As...
Dec 14, 2023 | Linda Huguelet, SGL Blogs
Abstracts related to multiple myeloma once again dominated ASH and a record number of attendees were there to absorb all the information. Of the 7,000 abstracts submitted, over 1,000 pertained to myeloma. 136 were presented orally, and 850 were presented as posters....
